[Management of malaria in Togolese communities]. / Prise en charge du paludisme dans les communautés du Togo.

The objective of this study was to collect community basis data on prevention and home management of malaria for the future assessment of "Roll Back Malaria", the new world strategy of fighting against malaria. The study was carried out in 3 districts in Togo. Mothers were questioned about the quality of home management of uncomplicated malaria on 951 children aged under 5. Fathers were questioned about the use of mosquito bed nets in 597 households, and 246 women were interviewed about the prevention of malaria during pregnancy. Home management of children under treatment was correct in only 38.1% of cases and the drug observance was followed by only 35.4% of patients. Mosquito nets were used in 30.5% of households and only 16.5% were treated with insecticides. Only 22.7% of children under 5 slept under mosquito nets. 80% women made at least one antenatal visit and 74.4% received regular malaria chemoprophylaxis. Many efforts should be made in Togo to increase the quality of home management of malaria and the use of insecticide-treated bed nets.

[White blood cells counts and parasite density in malaria in children aged 6 to 60 months in urban areas of Togo]. / Numération leucocytaire et densité parasitaire dans le paludisme simple chez les enfants âgés de 6 mois à 5 ans en milieu urbain au Togo.

Rational use of the artemisinin-based combination therapies in Togo requires laboratory parasitemia values to confirm suspected malaria. This study was conducted to determine the impact of the measured white blood cell (WBC) count on the determination of malaria parasite density among children younger than 5 years old infected with uncomplicated Plasmodium falciparum in Togo. This cross-sectional study of 267 children from four pediatric centers diagnosed malaria with both thick and thin blood smears and counted WBCs with a hematology analyzer. The parasite densities, calculated with the number of WBCs and estimated with an assumed count of 8,000/µL, were compared with the Wilcoxon matched pairs signed-rank test. The children's median age was 35 months (interquartile range [24-48]), with a sex ratio of 1.32. The median WBC value was 8,300 cells/µL (range: 1,300-24,900 cells/µL). The median parasitemia value calculated with the absolute WBC count was 35,714 (range: 139-48,860 parasites/µL) was not statistically different from that estimated with the assumed value of 8,000 cells/µL - 33 125 parasites/µL (p = 0.564). This study shows that malaria parasite density obtained by assuming 8000 cells/µL does not result in overestimations for children aged 6-59 months.

Chloroquine efficacy in the treatment of uncomplicated malaria at three sentinel sites in northern Togo.

In Togo, chloroquine (CQ) remains the first-line drug for the treatment of uncomplicated, Plasmodium falciparum malaria. In the absence of recent data on the level of parasite resistance to antimalarial drugs, Togo's National Malaria Control Programme (NMCP) decided to assess the current efficacy of CQ in the treatment of uncomplicated, P. falciparum malaria at three sentinel sites in the north of the country. Between the September and November of 2001, the World Health Organization's standard 14-day protocol was used to investigate 153 malarious children aged 6-59 months old (46 from Sokode, 54 from Niamtougou and 53 from Dapaong). Of the subjects from Sokode, Niamtougou and Dapaong, early treatment failure was observed in 0%, 7% and 12%, late treatment failure in 0%, 11% and 17%, and overall parasitological failure in 0%, 45% [with a 95% confidence interval (CI) of 39%-51%] and 62% (CI=54%-70%), respectively. Even within northern Togo, there is clearly considerable geographical variation in the level of resistance to CQ. Before an efficient antimalarial-drug policy can be developed, there is an urgent need to develop and use the national surveillance system further, to collect relevant data on the efficacies of CQ and other antimalarial drugs, such as amodiaquine and sulfadoxine-pyrimethamine.